Skip to main content

Table 1 Background of ACA+ and ACA- SS patients in this study

From: Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study

 

ACA (+)

ACA (-)

P value

N (M/F)

14 (0/14)

48 (1/47)

0.59

Age

57.4 ± 9.6

58.3 ± 13.2

0.82

Follow-up period (year)

6.6 ± 5.6

4.5 ± 4.6

0.16

Raynaud's phenomenon

8/13 (61.5%)

4/48 (8.3%)

1.86 × 10-5

anti-SS-A/Ro Ab or anti-SS-B/La Ab

0/14 (0.0%)

37/48 (77.1%)

2.30 × 10-7

IgG (mg/dl)

1530.2 ± 267.1

2056.0 ± 730.2

0.018

Average of FS

1.4 ± 1.0

2.3 ± 1.6

0.035

  1. Clinical characteristics of the ACA-seropositive and non-ACA Sjögren's syndrome (SS) patients are shown. The differences were calculated using Student's t test and the Chi-square test. (*; p < 0.05; statistically significant). The differences found regarded the prevalence of Raynaud's phenomenon, the level of IgG and the average of FS.
  2. Follow-up period is duration from point of diagnosis. ACA; anti-centromere antibody, FS; focus score
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us